Particular care is needed for patients who are transferred from systemically active corticosteroids to ASMANEX TWISTHALER
because deaths due to adrenal insufficiency have occurred in asthmatic patients during and after transfer from systemic corticosteroids to less systemically available inhaled corticosteroids.
Mode of Action 39 Approvals 39 Patents 39 Generic Company Activity 40 Mylan 40 Actavis 40 Prasco Laboratories 40 Teva 41 US Generic Approvals 41 Market Outlook 41 Asmanex Twisthaler
(mometasone furoate) 43 Mode of Action 43 Approvals 43 Patents 44 Generic Company Activity 44 Market Outlook 44 Alvesco (ciclesonide) 46 Mode of Action 46 Approvals 46 Patents 46 Generic Company Activity 47 Market Outlook 47 Combivent (ipratropium bromide+ salbutamol[albuterol]) 48 Mode of Action 48 Approvals 48 Patents 48 Generic Company Activity 49 Market Outlook 49 Spiriva (tiotropium bromide) 51
is also for asthma patients who are taking oral steroids where it may reduce or eliminate the need for oral steroids.
Important Information about ASMANEX TWISTHALER
in the U.
(mometasone furoate inhalation powder) is for the maintenance treatment of asthma in patients 4 years of age and older.
the company's country operation in Japan, has received marketing approval for ASMANEX TWISTHALER
(mometasone furoate dry powder inhaler) for the treatment of bronchial asthma in adults.
The ASMANEX TWISTHALER
employs an inhalation-driven device that does not use a propellant, thus eliminating the need for hand-breath coordination, and it provides patients with a numeric dose counter that provides a visual indication of the remaining doses.
31, 2008) -- Gained FDA approval of ASMANEX TWISTHALER
(mometasone furoate inhalation powder) for the maintenance treatment of asthma as a preventive therapy in patients 4 to 11 years of age.
therapy should not be used to treat sudden asthma attacks.
Announced July 28) -- Reported nationwide availability of ASMANEX TWISTHALER
220 mcg (mometasone furoate inhalation powder), an inhaled corticosteroid approved by the FDA for the maintenance treatment of asthma for patients 12 years of age and older, in conjunction with announcing results of an asthma survey.
helps provide round-the-clock control of asthma symptoms.
approval of ASMANEX TWISTHALER
220 mcg (announced March 31) for the first-line maintenance treatment of asthma as preventive therapy in patients 12 years of age and older.